Denna sida på svenska
Loading profile information...

Education

1990 – Ph.D. in Neurochemistry, Stockholm University.

1991-1994 – Postdoctoral Fellow, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York.

1994-1995 – Assistant Professor, Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York.

1996-2000 – Assistant Professor, Department of Neuroscience, Karolinska Institutet.

2000-2006 – Associate Professor, Department of Neuroscience, Karolinska Institutet.

From 2006 – Professor of Neuroscience, Department of Neuroscience, Karolinska Institutet.

 

Research description

We study signal transduction mechanisms involved in neurodegenerative and neuropsychiatric disorders, such as Parkinson’s disease, schizophrenia and drug addiction. We have been particularly interested in the study of dopamine transmission, which is profoundly affected in all these conditions.

Our final goal is to identify molecular changes, which may represent novel targets for therapeutic interventions. Methodology is based on a combination of molecular biological, biochemical and behavioral techniques. Disease modelling coupled to cell-targeted expression of fluorescent proteins is used to investigate abnormal signaling and gene expression at the level of discrete groups of neurons. In parallel, specific signaling components are studied at the biochemical and behavioral level using pharma­cological tools, or by manipulating their expression both systemically and in a cell-specific manner. Using these strategies we have characterized key molecular events involved in the effects of various classes of psychoactive drugs. We have also identified abnormalities in signal transduction affecting distinct neuronal populations and underlying the severe motor complications, or dyskinesia, caused by prolonged administration of L-DOPA to parkinsonian patients. More recently, we have started to investigate the mechanisms at the basis of non-motor symptoms of PD, which include cognitive impairment and neuropsychiatric conditions, such as depression and anxiety.

We are also studying the effects of typical and atypical antipsychotic drugs on signal transduction processes in various brain regions.

Publications

Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model
Rivetti Di Val Cervo P, Romanov Ra, Spigolon G, Masini D, Martín-montañez E, Toledo Em, et al
Nature biotechnology 2017;35(5):444-452

l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?
Carta Ar, Mulas G, Bortolanza M, Duarte T, Pillai E, Fisone G, et al
EUROPEAN JOURNAL OF NEUROSCIENCE 2017;45(1):73-91

The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism
Masini D, Lopes-aguiar C, Bonito-oliva A, Papadia D, Andersson R, Fisahn A, et al
Translational psychiatry 2017;7(4):e1088-

A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression
Feyder M, Södersten E, Santini E, Vialou V, Laplant Q, Watts El, et al
Biological psychiatry 2016;79(5):362-71

Differential regulation of the phosphorylation of Trimethyl-lysine27 histone H3 at serine 28 in distinct populations of striatal projection neurons
Bonito-oliva A, Södersten E, Spigolon G, Hu X, Hellysaz A, Falconi A, et al
Neuropharmacology 2016;107():89-99

Involvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine
Bonito-oliva A, Dupont C, Madjid N, Ogren So, Fisone G
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 2016;19(6):-

Somatosensory map expansion and altered processing of tactile inputs in a mouse model of fragile X syndrome
Juczewski K, Von Richthofen H, Bagni C, Celikel T, Fisone G, Krieger P
Neurobiology of disease 2016;96():201-215

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide Mf, Meissner Wg, Picconi B, Fasano S, Fernagut Po, Feyder M, et al
Progress in neurobiology 2015;132():96-168

Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice
Mango D, Bonito-oliva A, Ledonne A, Cappellacci L, Petrelli R, Nisticò R, et al
Experimental neurology 2014;261():733-43

A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions
Bonito-oliva A, Masini D, Fisone G
Frontiers in behavioral neuroscience 2014;8():290-

Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism
Bonito-oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F, et al
Biological psychiatry 2014;75(9):701-10

Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism
Södersten E, Feyder M, Lerdrup M, Gomes Al, Kryh H, Spigolon G, et al
PLoS genetics 2014;10(9):e1004574-

Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions
Mango D, Bonito-oliva A, Ledonne A, Nistico R, Castelli V, Giorgi M, et al
NEUROPHARMACOLOGY 2014;:127-36

Understanding the role of heteroreceptor complexes in the central nervous system
Fuxe K, Borroto-escuela D, Fisone G, Agnati Lf, Tanganelli S
Current protein & peptide science 2014;15(7):647-

Dopamine-Dependent Long-Term Depression at Subthalamo-Nigral Synapses Is Lost in Experimental Parkinsonism
Dupuis Jp, Feyder M, Miguelez C, Garcia L, Morin S, Choquet D, et al
JOURNAL OF NEUROSCIENCE 2013;33(36):14331-41

Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease
Amalric M, Lopez S, Goudet C, Fisone G, Battaglia G, Nicoletti F, et al
NEUROPHARMACOLOGY 2013;:53-64

Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1
Bonito-oliva A, Pallottino S, Bertran-gonzalez J, Girault Ja, Valjent E, Fisone G
Neuropharmacology 2013;72():197-203

mGlu5R promotes glutamate AMPA receptor phosphorylation via activation of PKA/DARPP-32 signaling in striatopallidal medium spiny neurons
Dell'anno Mt, Pallottino S, Fisone G
Neuropharmacology 2013;66():179-86

Operant behavior to obtain palatable food modifies ERK activity in the brain reward circuit
Guegan T, Cutando L, Gangarossa G, Santini E, Fisone G, Martinez A, et al
EUROPEAN NEUROPSYCHOPHARMACOLOGY 2013;23(3):240-52

Operant behavior to obtain palatable food modifies neuronal plasticity in the brain reward circuit
Guegan T, Cutando L, Ayuso E, Santini E, Fisone G, Bosch F, et al
EUROPEAN NEUROPSYCHOPHARMACOLOGY 2013;23(2):146-59

Prion formation correlates with activation of translation-regulating protein 4E-BP and neuronal transcription factor Elk1
Allard Ek, Grujic M, Fisone G, Kristensson K
Neurobiology of disease 2013;58():116-22

Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models
Solari N, Bonito-oliva A, Fisone G, Brambilla R
LEARNING & MEMORY 2013;20(10):592-600

Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism
Santini E, Feyder M, Gangarossa G, Bateup Hs, Greengard P, Fisone G
The Journal of biological chemistry 2012;287(33):27806-12

Dyskinesia in Parkinson's Disease Therapy
Carta Ar, Giuffrida A, Fisone G
PARKINSONS DISEASE 2012;:639080-

Neuronal signaling and behavior
Fisone G, Brambilla R
Frontiers in behavioral neuroscience 2012;6():72-

Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease
Lopez S, Bonito-oliva A, Pallottino S, Acher F, Fisone G
Journal of Parkinson's disease 2011;1(4):339-46

Convulsant Doses of a Dopamine D1 Receptor Agonist Result in Erk-Dependent Increases in Zif268 and Arc/Arg3.1 Expression in Mouse Dentate Gyrus
Gangarossa G, Di Benedetto M, O'sullivan Gj, Dunleavy M, Alcacer C, Bonito-oliva A, et al
PLOS ONE 2011;6(5):e19415-

Deciphering the actions of antiparkinsonian and antipsychotic drugs on cAMP/DARPP-32 signaling
Bonito-oliva A, Feyder M, Fisone G
FRONTIERS IN NEUROANATOMY 2011;:38-

Haloperidol Regulates the State of Phosphorylation of Ribosomal Protein S6 via Activation of PKA and Phosphorylation of DARPP-32
Valjent E, Bertran-gonzalez J, Bowling H, Lopez S, Santini E, Matamales M, et al
NEUROPSYCHOPHARMACOLOGY 2011;36(12):2561-70

Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia
Errico F, Bonito-oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, et al
EXPERIMENTAL NEUROLOGY 2011;232(2):240-50

L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission
Feyder M, Bonito-oliva A, Fisone G
FRONTIERS IN BEHAVIORAL NEUROSCIENCE 2011;:71-

MOLECULAR MECHANISMS OF L-DOPA-INDUCED DYSKINESIA
Fisone G, Bezard E
PATHOPHYSIOLOGY, PHARMACOLOGY, AND BIOCHEMISTRY OF DYSKINESIA 2011;:95-122

Development of Novel PDE1 Inhibitors as Dose-Sparing Medications in Parkinson's Disease
Snyder Gl, Vanover Ke, Zhu H, Zhang L, Li P, Hendrick Jp, et al
MOVEMENT DISORDERS 2010;:S664-S665

Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia
Santini E, Sgambato-faure V, Li Q, Savasta M, Dovero S, Fisone G, et al
PLOS ONE 2010;5(8):e12322-

Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors
Bateup Hs, Santini E, Shen Wx, Birnbaum S, Valjent E, Surmeier Dj, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010;107(33):14845-50

Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia
Napolitano F, Pasqualetti M, Usiello A, Santini E, Pacini G, Sciamanna G, et al
NEUROBIOLOGY OF DISEASE 2010;38(3):434-45

ITI-007: A Novel Treatment for Sleep Disorders and Dyskinesia in Parkinson's Disease
Vanover Ke, Davis Re, Snyder Gl, Hendrick Jp, Fisone G, Fienberg Aa, et al
MOVEMENT DISORDERS 2010;:S664-S664

Monitoring dyskinesia with Zif
Fisone G
EXPERIMENTAL NEUROLOGY 2010;226(1):11-4

mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia A sensitized matter
Santini E, Valjent E, Fisone G
CELL CYCLE 2010;9(14):2713-8

Histone H3 Phosphorylation is Under the Opposite Tonic Control of Dopamine D2 and Adenosine A2A Receptors in Striatopallidal Neurons
Bertran-gonzalez J, Hakansson K, Borgkvist A, Irinopoulou T, Brami-cherrier K, Usiello A, et al
NEUROPSYCHOPHARMACOLOGY 2009;34(7):1710-20

Inhibition of mTOR Signaling in Parkinson's Disease Prevents L-DOPA-Induced Dyskinesia
Santini E, Heiman M, Greengard P, Valjent E, Fisone G
SCIENCE SIGNALING 2009;2(80):ra36-

l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice
Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P, et al
JOURNAL OF NEUROCHEMISTRY 2009;108(3):621-33

Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice
Valjent E, Bertran-gonzalez J, Herve D, Fisone G, Girault Ja
TRENDS IN NEUROSCIENCES 2009;32(10):538-47

Opposing effects of ERK and p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells
Nordstrom E, Fisone G, Kristensson K
FASEB JOURNAL 2009;23(2):613-22

Antagonistic cannabinoid CB1/dopamine D-2 receptor interactions in striatal CB1/D-2 heteromers. A combined neurochemical and behavioral analysis
Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, et al
NEUROPHARMACOLOGY 2008;54(5):815-23

D-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801
Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, et al
JOURNAL OF NEUROSCIENCE 2008;28(41):10404-14

Delayed, context- and dopamine D1 receptor-dependent activation of ERK in morphine-sensitized mice
Borgkvist A, Valjent E, Santini E, Herve D, Girault Ja, Fisone G
NEUROPHARMACOLOGY 2008;55(2):230-7

Dopamine D-1 vs D-5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling
O'sullivan Gj, Dunleavy M, Hakansson K, Clementi M, Kinsella A, Croke Dt, et al
NEUROPHARMACOLOGY 2008;54(7):1051-61

EXPRESSION OF X-CHROMOSOME LINKED INHIBITOR OF APOPTOSIS PROTEIN IN MATURE PURKINJE CELLS AND IN RETINAL BIPOLAR CELLS IN TRANSGENIC MICE INDUCES NEURODEGENERATION
Korhonen L, Hansson I, Maugras C, Wehrle R, Kairisalo M, Borgkvist A, et al
NEUROSCIENCE 2008;156(3):515-26

Involvement of DARPP-32, FosB, and dynorphin in voluntary wheel running
Borgkvist A, Nestler Ej, Greengard P, Fisone G, Brene S
EUROPEAN NEUROPSYCHOPHARMACOLOGY 2008;:S5-S6

Lrrk2 and alpha-synuclein are co-regulated in rodent striatum
Westerlund M, Ran C, Borgkvist A, Sterky Fh, Lindqvist E, Lundstromer K, et al
MOLECULAR AND CELLULAR NEUROSCIENCE 2008;39(4):586-91

Parkinson's disease: Levodopa-induced dyskinesia and signal transduction
Santini E, Valjent E, Fisone G
FEBS JOURNAL 2008;275(7):1392-9

Regulation of DARPP-32 phosphorylation by Delta(9)-tetrahydrocannabinol
Borgkvist A, Marcellino D, Fuxe K, Greengard P, Fisone G
NEUROPHARMACOLOGY 2008;54(1):31-5

The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons
Errico F, Santini E, Migliarini S, Borgkvist A, Centonze D, Nasti V, et al
MOLECULAR AND CELLULAR NEUROSCIENCE 2008;37(2):335-45

Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward
Borgkvist A, Usiello A, Greengard P, Fisone G
NEUROPSYCHOPHARMACOLOGY 2007;32(9):1995-2003

Adenosine A(2A) receptors and basal ganglia physiology
Schiffmann Sn, Fisone G, Moresco R, Cunha Ra, Ferre S
PROGRESS IN NEUROBIOLOGY 2007;83(5):277-92

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia
Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault Ja, et al
JOURNAL OF NEUROSCIENCE 2007;27(26):6995-7005

Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons
Borgkvist A, Fisone G
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS 2007;31(1):79-88

Signaling in the basal ganglia: Postsynaptic and presynaptic mechanisms
Fisone G, Hakansson K, Borgkvist A, Santini E
PHYSIOLOGY & BEHAVIOR 2007;92(1-2):8-14

Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant mice
Borgkvist A, Puelles E, Carta M, Acampora D, Ang Sl, Wurst W, et al
MOLECULAR AND CELLULAR NEUROSCIENCE 2006;31(2):293-302

Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D-2 receptors
Hakansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G
JOURNAL OF NEUROCHEMISTRY 2006;96(2):482-8

Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons
Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg Aa, et al
JOURNAL OF NEUROSCIENCE 2005;25(37):8432-8

Increased D-1 dopamine receptor signaling in levodopa-induced dyskinesia
Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al
ANNALS OF NEUROLOGY 2005;57(1):17-26

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors
Guigoni C, Aubert I, Li Q, Gurevich Vv, Benovic Jl, Ferry S, et al
PARKINSONISM & RELATED DISORDERS 2005;:S25-9

Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia
Lundblad N, Usiello A, Carta M, Hakansson K, Fisone G, Cenci Ma
EXPERIMENTAL NEUROLOGY 2005;194(1):66-75

Caffeine as a psychomotor stimulant: mechanism of action
Fisone G, Borgkvist A, Usiello A
CELLULAR AND MOLECULAR LIFE SCIENCES 2004;61(7-8):857-72

DARPP-32 anal modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia
Hakansson K, Lindskog M, Pozzi L, Usiello A, Fisone G
PARKINSONISM & RELATED DISORDERS 2004;10(5):281-6

Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol
Hakansson K, Pozzi L, Usiello A, Haycock J, Borrelli E, Fisone G
EUROPEAN JOURNAL OF NEUROSCIENCE 2004;20(4):1108-12

The role of DARPP-32 in the actions of drugs of abuse
Nairn Ac, Svenningsson P, Nishi A, Fisone G, Girault Ja, Greengard P
NEUROPHARMACOLOGY 2004;:14-23

Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites
Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003;100(7):4305-9

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al
NATURE NEUROSCIENCE 2003;6(5):501-6

Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum
Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Greengard P, et al
JOURNAL OF NEUROCHEMISTRY 2003;86(2):451-9

Plasma membrane and vesicular glutamate transporter mRNAs/proteins in hypothalamic neurons that regulate body weight
Collin M, Backberg M, Ovesjo Ml, Fisone G, Edwards Rh, Fujiyama F, et al
EUROPEAN JOURNAL OF NEUROSCIENCE 2003;18(5):1265-78

Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain
Lindgren N, Goiny M, Herrera-marschitz M, Haycock Jw, Hokfelt T, Fisone G
EUROPEAN JOURNAL OF NEUROSCIENCE 2002;15(4):769-73

Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine
Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg Aa, Bibb Ja, et al
NATURE 2002;418(6899):774-8

Some aspects on the anatomy and function of central cholecystokinin systems
Hokfelt T, Blacker D, Broberger C, Herrera-marschitz M, Snyder G, Fisone G, et al
PHARMACOLOGY & TOXICOLOGY 2002;91(6):382-6

Dopamine D-2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum
Lindgren N, Xu Zqd, Herrera-marschitz M, Haycock J, Hokfelt T, Fisone G
EUROPEAN JOURNAL OF NEUROSCIENCE 2001;13(4):773-80

The effects of adenosine and caffeine on locomotor activity are mediated via DARPP-32 phosphorylation
Lindskog M, Svenningsson P, Fienberg A, Bibb J, Greengard P, Fredholm B, et al
NORDIC JOURNAL OF PSYCHIATRY 2001;55(2):97-97

Dopamine D-1 receptor-induced gene transcription is modulated by DARPP-32
Svenningsson P, Fienberg Aa, Allen Pb, Le Moine C, Lindskog M, Fisone G, et al
JOURNAL OF NEUROCHEMISTRY 2000;75(1):248-57

Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D-1, dopamine D-2, and adenosine A(2A) receptors
Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm Bb, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2000;97(4):1856-60

Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum
Lindgren N, Xu Zqd, Lindskog M, Herrera-marschitz M, Goiny M, Haycock J, et al
JOURNAL OF NEUROCHEMISTRY 2000;74(6):2470-7

Activation of dopamine D-2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms
Lindskog M, Svenningsson P, Fredholm Bb, Greengard P, Fisone G
NEUROSCIENCE 1999;88(4):1005-8

Distribution, biochemistry and function of striatal adenosine A(2A) receptors
Svenningsson P, Le Moine C, Fisone G, Fredholm Bb
PROGRESS IN NEUROBIOLOGY 1999;59(4):355-96

mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons
Lindskog M, Svenningsson P, Fredholm B, Greengard P, Fisone G
EUROPEAN JOURNAL OF NEUROSCIENCE 1999;11(6):2182-6

Regulation of Na+,K+-ATPase isoforms in rat neostriatum by dopamine and protein kinase C
Nishi A, Fisone G, Snyder Gl, Dulubova I, Aperia A, Nairn Ac, et al
JOURNAL OF NEUROCHEMISTRY 1999;73(4):1492-501

Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation
Nishi A, Snyder Gl, Fienberg Aa, Fisone G, Aperia A, Naim Ac, et al
EUROPEAN JOURNAL OF NEUROSCIENCE 1999;11(7):2589-92

Activation of adenosine A(2A) and dopamine D-1 receptors stimulates cyclic AMP dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons
Svenningsson P, Lindskog M, Rognoni F, Fredholm Bb, Greengard P, Fisone G
NEUROSCIENCE 1998;84(1):223-8

Effects of okadaic acid, calyculin A, and PDBu on state of phosphorylation of rat renal Na+-K+-ATPase
Li Dl, Cheng Sxj, Fisone G, Caplan Mj, Ohtomo Y, Aperia A
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 1998;275(6):F863-9

Na+,K+-ATPase phosphorylation in the choroid plexus: Synergistic regulation by serotonin/protein kinase C and isoproterenol/cAMP-PK/PP-1 pathways
Fisone G, Snyder Gl, Aperia A, Greengard P
MOLECULAR MEDICINE 1998;4(4):258-65

The DARPP-32 protein phosphatase-1 cascade: a model for signal integration
Greengard P, Nairn Ac, Girault Ja, Ouimet Cc, Snyder Gl, Fisone G, et al
BRAIN RESEARCH REVIEWS 1998;26(2-3):274-84

PKA-mediated phosphorylation and inhibition of Na+-K+-ATPase in response to beta-adrenergic hormone
Cheng Xj, Fisone G, Aizman O, Aizman R, Levenson R, Greengard P, et al
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY 1997;273(3):C893-901

Phosphorylation & inhibition of renal Na,K-ATPase in response to beta-adrenergic hormone.
Cheng Xj, Fisone G, Aizman O, Aizman R, Levenson R, Greengard P, et al
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 1996;7(9):A0152-A0152

NA+,K+-ATPASE IN THE CHOROID-PLEXUS - REGULATION BY SEROTONIN PROTEIN-KINASE-C PATHWAY
Fisone G, Snyder Gl, Fryckstedt J, Caplan Mj, Aperia A, Greengard P
JOURNAL OF BIOLOGICAL CHEMISTRY 1995;270(6):2427-30

Show all publications